FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2907449476> ?p ?o ?g. }

• W2907449476 endingPage "1135" @default.
• W2907449476 startingPage "1128" @default.
• W2907449476 abstract "Post-transplant cyclophosphamide (PTCy) can be used as the sole immunosuppression after myeloablative conditioning (MAC) for HLA-matched bone marrow transplantation (BMT). However, the effects of graft-versus-host disease (GVHD) with this platform are undefined. We retrospectively analyzed 298 consecutive adult patients with hematologic malignancies who engrafted after MAC HLA-matched sibling donor (MSD; n = 187) or HLA-matched unrelated donor (MUD; n = 111) T-cell–replete BMT with PTCy 50 mg/kg on days +3 and +4. After MSD and MUD BMT, 35% and 57% of patients, respectively, developed grade II acute GVHD (aGVHD) by 100 days, 11% and 14% grade III to IV aGVHD by 100 days, and 9% and 16% chronic GVHD (cGVHD) by 1 year. In landmark analyses at 100 days after HLA-matched BMT, 4-year overall survival (OS) and progression-free survival (PFS) were 57% (95% confidence interval [CI], .49 to .67) and 40% (95% CI, .31 to .51) in patients without grades II to IV aGVHD, and 68% (95% CI, .59 to .78) and 54% (95% CI, .44 to .65) in patients with grade II aGVHD. In adjusted time-dependent multivariable analyses, grade II aGVHD was associated with improved OS (hazard ratio, .58; 95% CI, .37 to .89; P = .01) and PFS (hazard ratio, .50; 95% CI, .34 to .74; P < .001) after HLA-matched BMT with PTCy. The ability of PTCy to limit grades III to IV aGVHD and cGVHD while maintaining grade II aGVHD may contribute to its effectiveness, and further attempts to reduce aGVHD may be detrimental." @default.
• W2907449476 created "2019-01-11" @default.
• W2907449476 creator A5002822530 @default.
• W2907449476 creator A5003078712 @default.
• W2907449476 creator A5007801126 @default.
• W2907449476 creator A5008376801 @default.
• W2907449476 creator A5014659694 @default.
• W2907449476 creator A5027419360 @default.
• W2907449476 creator A5034547254 @default.
• W2907449476 creator A5036285787 @default.
• W2907449476 creator A5036664711 @default.
• W2907449476 creator A5046719320 @default.
• W2907449476 creator A5059680271 @default.
• W2907449476 creator A5065373363 @default.
• W2907449476 creator A5068492086 @default.
• W2907449476 creator A5068593672 @default.
• W2907449476 creator A5082236040 @default.
• W2907449476 creator A5083424368 @default.
• W2907449476 creator A5089094849 @default.
• W2907449476 date "2019-06-01" @default.
• W2907449476 modified "2023-10-16" @default.
• W2907449476 title "Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide" @default.
• W2907449476 cites W1274344746 @default.
• W2907449476 cites W1489421828 @default.
• W2907449476 cites W1491993932 @default.
• W2907449476 cites W1504310442 @default.
• W2907449476 cites W1780799486 @default.
• W2907449476 cites W1980889124 @default.
• W2907449476 cites W1996041033 @default.
• W2907449476 cites W2002547051 @default.
• W2907449476 cites W2005580937 @default.
• W2907449476 cites W2017000328 @default.
• W2907449476 cites W2017908149 @default.
• W2907449476 cites W2020725971 @default.
• W2907449476 cites W2039334806 @default.
• W2907449476 cites W2039642633 @default.
• W2907449476 cites W2055553511 @default.
• W2907449476 cites W2072290737 @default.
• W2907449476 cites W2073140442 @default.
• W2907449476 cites W2079023050 @default.
• W2907449476 cites W2121710010 @default.
• W2907449476 cites W2121964181 @default.
• W2907449476 cites W2127975197 @default.
• W2907449476 cites W2128812336 @default.
• W2907449476 cites W2133201432 @default.
• W2907449476 cites W2148233118 @default.
• W2907449476 cites W2152041770 @default.
• W2907449476 cites W2159507916 @default.
• W2907449476 cites W2166654361 @default.
• W2907449476 cites W2169530433 @default.
• W2907449476 cites W2379365975 @default.
• W2907449476 cites W2396016479 @default.
• W2907449476 cites W2416259506 @default.
• W2907449476 cites W2532403292 @default.
• W2907449476 cites W2532562305 @default.
• W2907449476 cites W2566555955 @default.
• W2907449476 cites W2618073389 @default.
• W2907449476 cites W2681369214 @default.
• W2907449476 cites W2766315387 @default.
• W2907449476 cites W2783728901 @default.
• W2907449476 cites W2800808649 @default.
• W2907449476 cites W3112391182 @default.
• W2907449476 cites W4293241248 @default.
• W2907449476 doi "https://doi.org/10.1016/j.bbmt.2018.12.767" @default.
• W2907449476 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6559825" @default.
• W2907449476 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30599208" @default.
• W2907449476 hasPublicationYear "2019" @default.
• W2907449476 type Work @default.
• W2907449476 sameAs 2907449476 @default.
• W2907449476 citedByCount "36" @default.
• W2907449476 countsByYear W29074494762019 @default.
• W2907449476 countsByYear W29074494762020 @default.
• W2907449476 countsByYear W29074494762021 @default.
• W2907449476 countsByYear W29074494762022 @default.
• W2907449476 countsByYear W29074494762023 @default.
• W2907449476 crossrefType "journal-article" @default.
• W2907449476 hasAuthorship W2907449476A5002822530 @default.
• W2907449476 hasAuthorship W2907449476A5003078712 @default.
• W2907449476 hasAuthorship W2907449476A5007801126 @default.
• W2907449476 hasAuthorship W2907449476A5008376801 @default.
• W2907449476 hasAuthorship W2907449476A5014659694 @default.
• W2907449476 hasAuthorship W2907449476A5027419360 @default.
• W2907449476 hasAuthorship W2907449476A5034547254 @default.
• W2907449476 hasAuthorship W2907449476A5036285787 @default.
• W2907449476 hasAuthorship W2907449476A5036664711 @default.
• W2907449476 hasAuthorship W2907449476A5046719320 @default.
• W2907449476 hasAuthorship W2907449476A5059680271 @default.
• W2907449476 hasAuthorship W2907449476A5065373363 @default.
• W2907449476 hasAuthorship W2907449476A5068492086 @default.
• W2907449476 hasAuthorship W2907449476A5068593672 @default.
• W2907449476 hasAuthorship W2907449476A5082236040 @default.
• W2907449476 hasAuthorship W2907449476A5083424368 @default.
• W2907449476 hasAuthorship W2907449476A5089094849 @default.
• W2907449476 hasBestOaLocation W29074494761 @default.
• W2907449476 hasConcept C126322002 @default.
• W2907449476 hasConcept C147483822 @default.
• W2907449476 hasConcept C188280979 @default.
• W2907449476 hasConcept C203014093 @default.

• next